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Abstract
Background: Oral tongue squamous cell carcinoma (SCC) is characterized by early
metastasis and poor prognosis. Interleukin-17F (IL-17F) plays a protective role in
many tumors. However, IL-17F expression in oral tongue SCC tissue has not been
investigated.
Methods: Immunostaining of 83 oral tongue SCC specimens and blinded-scoring
were used to map IL-17F expression, location, and distribution. Survival curves were
constructed according to Kaplan-Meier method. The Cox proportional hazard model
was applied for univariate and multivariate survival analyses.
Results: Mast cells are the major source of IL-17F in oral tongue SCC. In multivariate
analysis, only the extracellular mast cell-derived IL-17F at the tumor invasion front was
associated with better disease-specific survival in patients with all-stages and early-
stages of oral tongue SCC.
Conclusion: Extracellular mast cell-derived IL-17F is antitumorigenic in oral tongue
SCC. It separates patients with early-stage disease who are at high risk from patients
who are at low risk. Furthermore, when analyzing tentative prognostic molecules,
we conclude that in addition to the staining intensity, attention must be paid to the
cellular source, distribution, and location of the molecule.
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1 | INTRODUCTION
Oral tongue squamous cell carcinoma (SCC) is the most com-
mon type of oral cancer worldwide and accounts for more
than half of the malignant lesions in the oral cavity.1,2 The
incidence rate of oral tongue SCC has increased recently.
This increase is linked to several factors, including increased
consumption of alcohol and tobacco products.3–5 Despite
improved treatment approaches, oral tongue SCC therapy
remains challenging because of rapid local invasion and early
metastasis of the tumor cells to regional lymph nodes.6
Interleukin-17F (IL-17F) is the most recently character-
ized member of the IL-17 cytokine family. This family
includes 6 IL-17 cytokines, namely, IL-17A through F. Of
all IL-17 members, IL-17F shares the greatest homology
with IL-17A.7 Unlike IL-17A, which is known as a protu-
morigenic cytokine, IL-17F was shown to have an antitu-
morigenic effect in several cancer types through different
mechanisms.8,9 In colon cancer, IL-17F was reported as an
inhibitory molecule of tumor angiogenesis; we also showed
that IL-17F levels were significantly lower than those in non-
malignant control samples.10,11 Moreover, IL-17F inhibits
the proliferation of hematopoietic malignant cells, such as
mastocytoma and plasmocytoma.12 In addition, IL-17F pro-
vides a protective effect against hepatocellular carcinoma
through the inhibition of tumor angiogenesis.13 Interestingly,
IL-17F levels were lower in the serum of patients with oral
cancer than in the serum of patients with leukoplakia and
healthy controls.14 Altogether, such reports apparently sug-
gest an inverse relationship between IL-17F and tumorigene-
sis. However, local IL-17F expression and its putative role in
oral tongue SCC remain unknown. In this study, we
evaluated the cellular sources of IL-17F in oral tongue SCC
tissue sections and investigated its possible association with
patients’ prognosis and mortality.
2 | MATERIALS AND METHODS
This study was performed according to the REMARK guide-
lines for tumor marker prognostic studies.15
TABLE 1 Baseline characteristics of patients with oral tongue
squamous cell carcinoma
Patient clinical data
Total no. of
patients (%)
Age, years
<60 29 (34.9)
60 54 (65.1)
Range 17-88
Mean 64.23
Median 66
Sex
Male 48 (57.8)
Female 35 (42.2)
Tumor grade
I, well 21 (25.3)
II, moderate 53 (63.9)
III, poor 9 (10.8)
Tumor stage
Early, I-II 49 (59)
Late, III-IV 34 (41)
Depth of invasion
<4 mm 18 (21.7)
4 mm 65 (78.3)
Neck lymph nodes
Positive 33 (39.8)
Negative 50 (60.2)
Adjuvant therapy
No 39 (47)
Radiochemotherapy 24 (28.9)
Radiochemotherapy and chemotherapy 20 (24.1)
Recurrence
No 47 (56.6)
Yes 36 (43.4)
TABLE 2 Primary antibodies used for the immunofluorescence
staining
Antibody Source
Working dilution/
concentration
Goat anti-human,
polyclonal, IL-17F
R&D Systems,
Minneapolis, MN
1:100 (1 lg/mL)
Rabbit anti-human,
monoclonal, mast
cell tryptase
Abcam,
Cambridge, UK
1:500 (1 lg/mL)
Mouse anti-human,
monoclonal, CD8
Dako, Glostrup,
Denmark
1:100 (1.5 lg/mL)
Mouse anti-human,
monoclonal, CD4
Dako Cytomation,
Glostrup, Denmark
1:80 (3 lg/mL)
Mouse anti-human
monoclonal, CD56
Dako Cytomation,
Glostrup, Denmark
1:100 (3.62 lg/mL)
Mouse anti-human,
monoclonal, CD20
Dako Cytomation,
Glostrup, Denmark
1:200 (1.92 lg/mL)
Mouse anti-human,
monoclonal, CD163
Leica Biosystems,
Newcastle, UK
1:200 (15.5 lg/mL)
Abbreviation: IL, interleukin.
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2.1 | Patients
This multicenter study comprised 83 patients with oral
tongue SCC who were treated surgically at the Oulu and
Tampere University Hospitals during the period from 1990-
2010. Paraffin-embedded samples were obtained from the
Departments of Pathology at the Oulu and Tampere Univer-
sity Hospitals. All patients signed informed consent forms.
The data inquiry was approved by the National Supervisory
Authority for Welfare and Health (VALVIRA) and the
Ethics Committee of the Northern Ostrobothnia Hospital
District. The use of patient material for this study was
approved by the Northern Ostrobothnia Hospital District
Ethics Committee (statement #8/2006 and amendment 19/10/
2006). Detailed patient data are presented in Table 1.
2.2 | Immunohistochemical staining
Paraffin-embedded samples were cut into 5-lm-thick sec-
tions using Leica RM2255 microtome (Leica Microsystems,
Wetzlar, Germany). Immunohistochemical staining was per-
formed using the Goat on Rodent HRP-polymer kit (Biocare
Medical, Pacheco, CA). After deparaffinization, antigens
were retrieved in citrate buffer (Dako, Carpinteria, CA) for
15 minutes using a microwave and followed by 20-minute
cooling at room temperature. Endogenous peroxidase activity
was blocked with Dako Peroxidase blocking solution for 15
minutes. Polyclonal goat antihuman IL-17F primary antibody
(R&D Systems, Minneapolis, MN) at a concentration of 1
lg/mL was applied first for 30 minutes at 378C then over-
night at 48C. On the following day, goat probe was applied
for 15 minutes and followed by Goat on Rodent HRP-
TABLE 3 Scoring criteria of oral tongue squamous cell carcinoma
specimens
Score Description
Inflammatory cell distribution
0 Inflammatory cells are distributed mainly
in the tumor area
1 Inflammatory cells are distributed mainly
in the invasion front
2 Inflammatory cells are distributed evenly
in both areas
IL-17F expression by cancer cells
0 Negative
1 5%-75% of cancer cells are IL-17F-positive
2 >75% of cancer cells are IL-17F-positive
Inflammatory cell type
1 Predominance of mast cells over inflammatory cells
2 Predominance of inflammatory cells over mast cells
IL-17F localization within mast cells
1 IL-17F is expressed both intracellularly
and at the extracellular matrix
2 IL-17F is expressed only intracellularly
Abbreviation: IL, interleukin.
FIGURE 1 The scoring of the inflammatory cell distribution was
carried out in 2 areas: the tumor area and the invasion front (original mag-
nification32) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 4 Scoring results of oral tongue squamous cell carcinoma
specimens
Variables No. of patients (%)
Inflammatory cell pattern
0 14 (16.9)
1 22 (26.5)
2 47 (56.6)
IL-17F expression by cancer cells
0 63 (75.9)
1 15 (18.1)
2 5 (6)
Inflammatory cell type (invasion front)
1 50 (60.2)
2 33 (39.8)
Inflammatory cell type (tumor area)
1 14 (16.9)
2 67 (80.7)
IL-17F localization within mast cells (invasion front)
1 54 (65.1)
2 29 (34.9)
IL-17F localization within mast cells (tumor area)
1 62 (74.7)
2 21 (25.3)
Abbreviation: IL, interleukin.
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polymer for 15 minutes at room temperature. Color was
developed using diaminobenzidine tetrahydrochloride for 10
minutes and washed in dH2O. Counterstaining of the slides
was performed using Mayer’s hematoxylin solution (Sigma-
Aldrich, St. Louis, MO) and mounted in Mountex (HistoLab,
Gothenburg, Sweden).
2.3 | Immunofluorescence staining
After deparaffinization, antigen retrieval was performed
using a microwave oven (MicroMED T=T Mega Histopro-
cessing Labstation; Milestone Srl, Sorisole, Italy). Slides
were then treated with 0.5% triton X-100 for 10 minutes at
room temperature. Slides were washed 3 times (5 minutes
each wash) in phosphate-buffered saline (PBS) and incubated
in 10% normal serum for 1 hour. Serum was subsequently
blotted away and slides were incubated overnight at 48C in
primary antibodies (detailed antibody information is listed in
Table 2). Slides were washed 3 times (5 minutes each wash)
in PBS and incubated in fluorescein-conjugated secondary
antibodies (Alexa Fluor, Molecular Probes, Leiden, The
Netherlands) for 1 hour at room temperature. After 3 washes
(5 minutes each wash) in PBS, nuclei were counterstained
with 40,6-diamidino-2- phenylindole (DAPI; Sigma-Aldrich)
for 10 minutes at room temperature. Slides were mounted in
Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA). The specificity of each staining was confirmed
with staining controls.
FIGURE 2 Expression of interleukin (IL)-17F by oral tongue squamous cell carcinoma (SCC) cells. A, Tumor cells (black arrows) were IL-17F-
negative for most patients with oral tongue SCC. B, In other cases, 5%-75% of tumor cells (black arrows) were IL-17F-positive; C, in a few cases,>75% of
tumor cells (black arrows) were IL-17F-positive. D, Inflammatory cells (black arrows) showed strong expression for IL-17F. E, Expression of IL-17Fwas
detected inmast cells both intracellularly (black arrow) and extracellularly (blue arrow). Double immunofluorescence staining for IL-17F (green), mast cell
tryptase (red), and DAPI (blue) confirmed the presence of both the intracellular (white arrow, F) and extracellular (white arrow, G) patterns of IL-17F
expression. Original magnification A-D5310; E5363; and F-G53100 [Color figure can be viewed at wileyonlinelibrary.com]
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2.4 | Assessment of interleukin-17F
expression
Two independent researchers (R.A. and M.S.) analyzed IL-
17F staining; both researchers were blinded to the clinical
data. The scoring criteria are listed in Table 3. Inflammatory
cell distribution was scored in the tumor area and in the
invasion front (Figure 1). The number of IL-17F-positive
mast cells in the tumor area and invasion front was counted
from 3 randomly selected 203 magnification fields per slide.
2.5 | Imaging of stained specimens
A fully automated Leica DM6000 microscope together with
Leica DFC365-FX camera (Leica Microsystems) and a
BX61 Motorized System Microscope (Olympus Life and
Material Science Europa GmbH, Hamburg, Germany) were
used to image the immunostained slides. Representative
figures are presented in the Results section.
2.6 | Statistical analysis
Statistical analyses were performed using SPSS software pro-
gram version 24.0 (IBM SPSS Statistics, SPSS, Chicago, IL).
Life tables were calculated according to the Kaplan-Meier
method. Survival curves were compared with the log-rank test.
Univariate and multivariate survival analyses were performed
with the Cox’s proportional hazards model. In multivariate
analysis, the results were adjusted for age, sex, grade, stage,
depth of invasion, and lymph node metastasis. Because there
were no end points (cancer deaths) in the <4-mm depth of
invasion group among patients with early-stage oral tongue
SCC, no hazard ratios (HRs) could be calculated in reference
to this group. The Mann-Whitney U test was used to check the
statistical significance between the 2 groups. In all the analy-
ses, values .05 were regarded as statistically significant.
3 | RESULTS
3.1 | Inflammatory cells are evenly
distributed within oral tongue squamous
cell carcinoma
We first examined the distribution of inflammatory cells in
the scored layers of oral tongue SCC samples. The most fre-
quently observed pattern of the inflammatory cell infiltrate in
oral tongue SCC tissues was even distribution in the 2 areas
(56.6%) followed by a greater density of inflammatory cells
in the invasion front area (26.5%) and in the tumor area
(16.9%; Table 4).
3.2 | Mast cells are the major producer of
interleukin-17F in oral tongue squamous cell
carcinoma
We next analyzed the immunoexpression of IL-17F in cancer
and inflammatory cells. Cancer cells were IL-17F-negative
for the majority of the patients with oral tongue SCC (75.9%);
cancer cells positive for IL-17F were observed in some
patients (24.1%; Figure 2A-C; Table 4). Inflammatory cells
FIGURE 3 Double immunofluorescence staining of interleukin
(IL)-17F and inflammatory cell markers in oral tongue squamous cell car-
cinoma (SCC) tissues. A,Most of the mast cells expressed strong IL-17F
staining: blue5 nuclei (DAPI); red5mast cell tryptase; green5 IL-17F.
B, Some of the mast cells were negative for IL-17F. C, For CD4-positive
T helper cells, some cells showed faint IL-17F immunoreactivity; blue5
nuclei (DAPI); red5 CD4; and green5 IL-17F (original magnification
340 [Color figure can be viewed at wileyonlinelibrary.com]
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showed sporadically strong IL-17F expression (Figure 2D).
The IL-17F staining in the cells that have mast cell morphol-
ogy was either in the cytoplasm (intracellular) or extracellular
(Figure 2E). Double immunofluorescence staining using IL-
17F and mast cell tryptase antibodies confirmed the 2 patterns
of the staining (Figure 2F,G). Staining with both inflamma-
tory cell markers and IL-17F demonstrated that the majority
of mast cells were positive for IL-17F (Figure 3A) and only a
few were negative (Figure 3B). Some CD4-positive T helper
cells exhibited weak IL-17F immunoreactivity (Figure 3C).
On the other hand, CD20-positive B cells, CD8-positive
T cells, and CD163-positive macrophages were negative for
IL-17F (data not shown).
3.3 | Mast cells positive for interleukin-17F
are more common at the invasion front in oral
tongue squamous cell carcinoma
Mast cells positive for IL-17F were often seen in the invasion
front (60.2%; Figure 4A; Table 4). Other inflammatory cells
positive for IL-17F were more commonly located in the
tumor area (80.7%; Figure 4B; Table 4) and to a lesser extent
in the invasion front (39.8%; Table 4). The IL-17F-positive
mast cell count was higher in the invasion front compared to
the tumor area (P < .0001; Figure 4C).
3.4 | Extracellular mast cell interleukin-17F
expression is predominant in oral tongue
squamous cell carcinoma
Extracellular IL-17F from mast cells was predominant in
65.1% of patients at the invasion front and 74.7% of patients
at the tumor areas (Table 4). Additionally, extracellular IL-
17F from mast cells represented 57.4% of the total IL-17F-
positive mast cells at the tumor area and 59.9% at the inva-
sion front (Figure 4D).
3.5 | Extracellular interleukin-17F from the
invasion-front mast cells predicts the survival
outcome of patients with oral tongue squamous
cell carcinoma
We applied univariate analyses for the mast cell extracellular
IL-17F on cancer-specific deaths. Patients with extracellular
IL-17F in the invasion front had longer disease-specific sur-
vival (DSS) compared with patients with intracellular IL-17F
FIGURE 4 Inflammatory cell type in oral tongue squamous cell carcinoma (SCC). A,Mast cells were more frequent at the invasion front of oral
tongue SCC tissues. B, The other inflammatory cells were more frequent in the tumor area closer to the epithelial tissue. C, The count of interleukin (IL)-
17F-positivemast cells was significantly higher in the invasion front compared to the tumor area. D, Extracellular pattern of IL-17F frommast cells was
more frequent than the intracellular pattern both at the tumor area and at the invasion front (original magnification340 [Color figure can be viewed at
wileyonlinelibrary.com]
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expression. This was shown in all stages (HR 3.79, 95% con-
fidence interval [CI] 1.64-8.80, P 5 .001; Figure 5A, Table
5), in patients with early-stage (HR 4.99, 95% CI 1.28-19.38,
P 5 .01; Figure 5B, Table 6) and late-stage (HR 3.34, 95%
CI 1.11-10.06, P 5 .03; Figure 5C, Table 7) oral tongue
SCC.
Additionally, multivariate Cox’s proportional hazard
regression model analysis was built to evaluate further
the impact of IL-17F expression on DSS (n 5 83; 54
events). The IL-17F extracellular staining was signifi-
cantly associated with longer DSS in all stages (HR
3.24, 95% CI 1.35-7.79, P 5 .008), in patients with
early-stage (HR 4.18, 95% CI 1.01-17.26, P 5 .04)
but not with late-stage (HR 2.28, 95% CI 0.69-7.48,
P 5 .17) oral tongue SCC.
4 | DISCUSSION
Although IL-17F-mediated immunity is considered as a cru-
cial host defense mechanism against infections, IL-17F is
now believed to play a pivotal role in tumorigenesis.10–14 In
the present study, we showed for the first time that the
extracellular localization of IL-17F from mast cells at the
FIGURE 5 Survival curves of the invasion front mast cell interleukin (IL)-17F location in all stages, early-stage and late-stage oral tongue squamous cell
carcinoma (SCC). A, Kaplan-Meier curves representing themast cell IL-17F location in all stages, B, early-stage, and C, late-stage of patients with oral tongue
SCC [Color figure can be viewed at wileyonlinelibrary.com]
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invasion front is associated with improved overall survival
and prognostic outcomes for patients with oral tongue SCC.
Cancer cells produce various cytokines and chemokines
that recruit immune cells to the tumor site. Indeed, the
inflammatory component of the tumor microenvironment
includes a wide range of inflammatory cells, including neu-
trophils, macrophages, lymphocytes, and mast cells. These
cells can synthesize and produce a large amount of cytokines
and cytotoxic mediators.16,17 Among these cells, mast cells
are regarded as highly important components of the tumor
microenvironment and are involved in orchestrating immune
responses against the tumor cells.18 Furthermore, we showed
in a recent study that mast cell count was noticeably
increased in specimens of patients with oral tongue SCC
compared with those retrieved from patients with oral dys-
plasia and normal controls.19 In this context, it is interesting
to find that IL-17F immunoreactivity was most intense in
mast cells compared with the other inflammatory infiltrate
cells, such as lymphocytes. This finding suggests that mast
cells are the major cellular source of IL-17F in patients with
oral tongue SCC, which is consistent with other reports that
highlighted mast cells (as opposed to T cells) as the main
producers of IL-17F in human dermal tissue.20
Inflammatory cell distribution and interaction in tissues
are considered as significant features in interpreting the ther-
apeutic outcomes of many tumors.16,21 We recently observed
such an interaction between cancer and inflammatory cells in
a 3D human-derived in vitro model that demonstrated the
ability of inflammatory cells to influence cancer cell prolifer-
ation and invasion.22 Furthermore, our group previously
found a significant correlation between inflammatory cell
infiltrates and oral tongue SCC recurrence.23 In particular,
we reported that patients with samples rich in CD163-
positive cells, Foxp3-positive regulatory T cells, and CD80-
positive cells showed higher incidence of cancer recurrence
than in patients with a lower abundance of such cells.23
However, our findings in the present study suggest a non-
significant correlation between the morphometrical distribu-
tion of the total inflammatory cells and the clinical status of
patients with all-stages of oral tongue SCC.
TABLE 5 Cox regression univariate and multivariate analyses of disease-specific survival for patients with all stages of oral tongue squamous
cell carcinoma
Univariate analysis Multivariate analysis
Variables HR (95% CI) P value HR (95% CI) P value
Age, years
<60 1 1
60 2.51 (0.93-6.76) .06 2.72 (0.88-8.33) .08
Sex
Female 1 1
Male 1.99 (0.87-4.55) .10 1. 93 (0.77-4.83) .16
Tumor grade
I and II 1 1
III 1.77 (0.60-5.19) .30 2. 32 (0.70-7.65) .17
Depth of invasion
<4 mm 1 1
4 mm 1.42 (0.48-4.18) .52 1. 35 (0.42-4.34) .62
Tumor stage
Early, I-II 1 1
Late, III-IV 2.01 (0.87-4.57) .09 1.51 (0.53-4.29) .43
Lymph node metastasis
N0 1 1
N1 1.94 (0.85-4.43) .11 1.90 (0.63-5.69) .25
IL-17F localization for mast cells
Extracellular 1 1
Intracellular 3.79 (1.64-8.80) .001 3.24 (1.35-7.79) .008
Abbreviations: CI, confidence interval; HR, hazard ratio; IL, interleukin.
Figures in boldface indicate statistical significance.
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TABLE 6 Cox regression univariate and multivariate analyses of disease-specific survival for patients with early-stage oral tongue squamous
cell carcinoma
Univariate analysis Multivariate analysis
Variable HR (95% CI) P value HR (95% CI) P value
Age, years
<60 1 1
60 2.35 (0.49-11.05) .28 2.17 (0.33-14.41) .41
Sex
Female 1 1
Male 2.21 (0.62-7.85) .22 2.41 (0.40-14.41) .33
Tumor grade
I and II 1 1
III 2.01 (0.42-9.49) .38 2.18 (0.28-16.82) .45
Depth of invasion
<4 mm 1 1
4 mm a .24 a .96
IL-17F localization for mast cells
Extracellular 1 1
Intracellular 4.99 (1.28-19.38) .01 4.18 (1.01-17.26) .04
Abbreviations: CI, confidence interval; HR, hazard ratio; IL, interleukin.
aNone of the patients with <4 mm depth of invasion died because of their disease.
Figures in boldface indicates statistical significance.
TABLE 7 Cox regression univariate and multivariate analyses of disease-specific survival for patients with late-stage oral tongue squamous cell
carcinoma
Univariate analysis Multivariate analysis
Variables HR (95% CI) P value HR (95% CI) P value
Age, y
<60 1 1
60 2.99 (0.82-10.96) .09 2.63 (0.60-11.51) .19
Sex
Female 1 1
Male 1.80 (0.60-5.37) .29 1.31 (0.39-4.33) .65
Tumor grade
I and II 1 1
III 1.75 (0.38-7.94) .46 2.18 (0.39-11.98) .36
Depth of invasion
<4 mm 1 1
4 mm 0.41 (0.126-1.34) .14 0.54 (0.15-1.96) .35
IL-17F localization for mast cells
Extracellular 1 1
Intracellular 3.34 (1.11-10.06) .03 2.28 (0.69-7.48) .17
Abbreviations: CI, confidence interval; HR, hazard ratio; IL, interleukin.
Figures in boldface indicates statistical significance.
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Mast cells produce a large variety of effector molecules.
These molecules are released extracellularly either within
minutes of activation (acute phase of disease) or over hours
or even days (delayed or chronic phase).18 Despite the con-
troversial role of mast cells in carcinogenesis, several stud-
ies have reported that mast cells play a protective role in
human cancers and improve prognosis, such as in colorectal
and oral cancers.24–26 As for oral tongue cancer, the mast
cell count showed significant correlation with the tumor
stage but not tumor grade or lymph node metastasis.27
Here, we report that extracellular IL-17F from mast cells at
the invasion front was significantly associated with
improved overall prognosis of patients with oral tongue
SCC. This result is supported by the fact that intracellular
IL-17F is most probably nonfunctional because of the lack
of any known intracellular IL-17F receptors and, thus, can-
not initiate ligand-receptor responses.28,29 Similar phenom-
ena are also known for other inflammatory molecules, such
as histamine. Histamine remains inactive inside the granules
of mast cells until its release upon degranulation to the oral
mucosal environment.30
In conclusion, extracellular mast cell-derived IL-17F has
a protective role in oral tongue SCC. It also could separate
high-risk from low-risk patients with early-stage oral tongue
SCC. Furthermore, we have also demonstrated the importance
of the cellular source, distribution, and localization criteria in
the histopathological evaluation of tentative molecular bio-
markers. Unfortunately, the vast majority of biomarker stud-
ies still only evaluate the molecular expression intensity in
the cancer cells; even when the tumor microenvironment is
counted, only staining intensity is evaluated. Such criteria of
the studied molecules should be taken into consideration
before implementing their use in routine clinical practice.
There are, however, some limitations in our study, such as
the use of a semiquantitative immunohistological assessment
and the lack of functional IL-17F experiments; performance
of such experiments is warranted in the future.
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